Karyopharm presents phase 3 trial results at ASCO 2026

June 2, 2026 9:00 AM

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) presented results from its Phase 3 SENTRY trial at the 2026 American Society of Clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found